Standardized protocols should establish uniform definitions for angiogenesis biomarkers (e.g., VEGF isoform-specific assays) and AF endpoints (e.g., implantable loop recorder-confirmed episodes) to ensure cross-study comparability [4,75]. This evidence concerns the gene VEGFA and atrial fibrillation.